Thursday, May 29/2025 – 09:45 AM
The American ADA announced on Wednesday that it has obtained privileges to develop the bird flu vaccine in its last stages, in addition to the right to purchase doses, according to Reuters.
The United States cancels a $ 700 million financing for our moder
In January, Moderna received $ 590 million from the Biden administration to enhance the development of bird flu vaccine, and to support the expansion of clinical studies of up to five additional sub -types of influenza.
This was in addition to 176 million dollars granted by the US Department of Health and Humanitarian Services last year to complete the development and test of the late MRNA vaccine against the H5N1 bird influenza virus before the epidemic appeared.
The US Department of Health and Humanitarian Services told Reuters earlier this year that it is reviewing the agreements concluded by the Biden administration to produce the vaccine.
“The cancellation means that the government gets rid of what might be one of the most effective and speedy tools to combat bird flu outbreak,” said Amish Adja, a prominent researcher at the Johns Hopkins Health Security
A spokesman for the Ministry of Health and Humanitarian Services said that after a comprehensive internal review, the agency decided that the project does not fulfill scientific standards or safety expectations required for the continuation of federal investment.
Bird flu wounded 70 people, most of whom are farm workers, during the past year, as they spread aggressively among cattle herds and poultry swarms.
Health Minister Robert F. Kennedy Junior in the use of vaccines, and earlier this year he was criticized by some members of the US Congress after he suggested in a television interview that poultry farmers would allow the spread of bird flu without a deterrent among their herds to study chicken that did not get sick.
Our Modern said it is planning to explore alternatives for a late stage of developing and manufacturing the vaccine.
The company relied on revenue from the latest MRNA vaccines, including bird flu vaccine and the complex demo vaccine, to compensate for the low demand for the Kofid vaccine after the epidemic.
On Wednesday, Moderna said it had received positive temporary data from an intermediate stage of experience created to test the safety and immunity of the bird flu vaccine that targets the sub -type of H5 bird flu virus.
